In silico analysis of antiviral phytochemicals efficacy against Epstein–Barr virus glycoprotein H

References

• Abraham, M. J., Murtola, T., Schulz, R., Páll, S., Smith, J. C., Hess, B., & Lindahl, E. (2015). GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX, 1–2, 19–25. https://doi.org/https://doi.org/10.1016/j.softx.2015.06.001
   Google Scholar
• Adzhubei, I. A., Schmidt, S., Peshkin, L., Ramensky, V. E., Gerasimova, A., Bork, P., Kondrashov, A. S., & Sunyaev, S. R. (2010). A method and server for predicting damaging missense mutations. Nature Methods, 7(4), 248–249. https://doi.org/https://doi.org/10.1038/nmeth0410-248
   PubMed Web of Science ®Google Scholar
• Antoine, T. E., Park, P. J., & Shukla, D. (2013). Glycoprotein targeted therapeutics: A new era of anti-herpes simplex virus-1 therapeutics. Reviews in Medical Virology, 23(3), 194–208. https://doi.org/https://doi.org/10.1002/rmv.1740
   PubMed Web of Science ®Google Scholar
• Asthana, S., Hazarika, Z., Sarathi Nayak, P., Roy, J., Nath Jha, A., Mallick, B., & Jha, S. (2019). Insulin adsorption onto zinc oxide nanoparticle mediates conformational rearrangement into amyloid-prone structure with enhanced cytotoxic propensity. Biochimica et Biophysica Acta. General Subjects, 1863(1), 153–166. https://doi.org/https://doi.org/10.1016/j.bbagen.2018.10.004
   PubMed Web of Science ®Google Scholar
• Backovic, M., Jardetzky, T. S., & Longnecker, R. (2007). Hydrophobic residues that form putative fusion loops of Epstein–Barr virus glycoprotein b are critical for fusion activity. Journal of Virology, 81(17), 9596–9600. https://doi.org/https://doi.org/10.1128/JVI.00758-07
   PubMed Web of Science ®Google Scholar
• Bora, N., & Nath Jha, A. (2019). An integrative approach using systems biology, mutational analysis with molecular dynamics simulation to challenge the functionality of a target protein. Chemical Biology & Drug Design, 93(6), 1050–1060. https://doi.org/https://doi.org/10.1111/cbdd.13502
   PubMed Web of Science ®Google Scholar
• Borkotoky, S., Kumar Meena, C., & Murali, A. (2016). Interaction analysis of T7 RNA polymerase with heparin and its low molecular weight derivatives – An in silico approach. Bioinformatics and Biology Insights, 10, 155–166. https://doi.org/https://doi.org/10.4137/BBI.S40427
   PubMed Web of Science ®Google Scholar
• Bussi, G., Donadio, D., & Parrinello, M. (2007). Canonical sampling through velocity rescaling. The Journal of Chemical Physics, 126(1), 014101. https://doi.org/https://doi.org/10.1063/1.2408420
   PubMed Web of Science ®Google Scholar
• Bu, W., Joyce, M. G., Nguyen, H., Banh, D. V., Aguilar, F., Tariq, Z., Yap, M. L., Tsujimura, Y., Gillespie, R. A., Tsybovsky, Y., Andrews, S. F., Narpala, S. R., McDermott, A. B., Rossmann, M. G., Yasutomi, Y., Nabel, G. J., Kanekiyo, M., & Cohen, J. I. (2019). Immunization with components of the viral fusion apparatus elicits antibodies that neutralize Epstein–Barr virus in B cells and epithelial cells. Immunity, 50(5), 1305–1316.e6. https://doi.org/https://doi.org/10.1016/j.immuni.2019.03.010
   PubMed Web of Science ®Google Scholar
• Calland, N., Albecka, A., Belouzard, S., Wychowski, C., Duverlie, G., Descamps, V., Hober, D., Dubuisson, J., Rouillé, Y., & Séron, K. (2012). (−)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry. Hepatology (Baltimore, Md.), 55(3), 720–729. https://doi.org/https://doi.org/10.1002/hep.24803
   PubMed Web of Science ®Google Scholar
• Chang, L.-K., Wei, T.-T., Chiu, Y.-F., Tung, C.-P., Chuang, J.-Y., Hung, S.-K., Li, C., & Liu, S.-T. (2003). Inhibition of Epstein–Barr virus lytic cycle by (−)-epigallocatechin gallate. Biochemical and Biophysical Research Communications, 301(4), 1062–1068. https://doi.org/https://doi.org/10.1016/S0006-291X(03)00067-6
   PubMed Web of Science ®Google Scholar
• Chen, J., Jardetzky, T. S., & Longnecker, R. (2013). The large Groove found in the gH/gL structure is an important functional domain for Epstein–Barr virus fusion. Journal of Virology, 87(7), 3620–3627. https://doi.org/https://doi.org/10.1128/JVI.03245-12
   PubMed Web of Science ®Google Scholar
• Chen, J., Sathiyamoorthy, K., Zhang, X., Schaller, S., Perez White, B. E., Jardetzky, T. S., & Longnecker, R. (2018). Ephrin receptor A2 is a functional entry receptor for Epstein–Barr virus. Nature Microbiology, 3(2), 172–180. https://doi.org/https://doi.org/10.1038/s41564-017-0081-7
   PubMed Web of Science ®Google Scholar
• Chesnokova, L. S., Ahuja, M. K., & Hutt-Fletcher, L. M. (2014). Epstein–Barr virus glycoprotein gB and gHgL can mediate fusion and entry in trans, and heat can act as a partial surrogate for gHgL and trigger a conformational change in gB. Journal of Virology, 88(21), 12193–12201. https://doi.org/https://doi.org/10.1128/JVI.01597-14
   PubMed Web of Science ®Google Scholar
• Chesnokova, L. S., & Hutt-Fletcher, L. M. (2011). Fusion of Epstein–Barr virus with epithelial cells can be triggered by αvβ5 in addition to αvβ6 and αvβ8, and integrin binding triggers a conformational change in glycoproteins gHgL. Journal of Virology, 85(24), 13214–13223. https://doi.org/https://doi.org/10.1128/JVI.05580-11
   PubMed Web of Science ®Google Scholar
• Cui, X., Cao, Z., Chen, Q., Arjunaraja, S., Snow, A. L., & Snapper, C. M. (2016). Rabbits Immunized with Epstein–Barr virus gH/gL or gB recombinant proteins elicit higher serum virus neutralizing activity than gp350. Vaccine, 34(34), 4050–4055. https://doi.org/https://doi.org/10.1016/j.vaccine.2016.06.021
   PubMed Web of Science ®Google Scholar
• Das, S., Hazarika, Z., Sarmah, S., Baruah, K., Rohman, M. A., Paul, D., Jha, A. N., & Roy, A. S. (2020a). Exploring the interaction of bioactive kaempferol with serum albumin, lysozyme and hemoglobin: A biophysical investigation using multi-spectroscopic, docking and molecular dynamics simulation studies. Journal of Photochemistry and Photobiology. B, Biology, 205, 111825. https://doi.org/https://doi.org/10.1016/j.jphotobiol.2020.111825
   PubMed Web of Science ®Google Scholar
• Das, S., Sarmah, S., Hazarika, Z., Rohman, M. A., Sarkhel, P., Jha, A. N., & Singha Roy, A. (2020b). Targeting the heme protein hemoglobin by (−)-epigallocatechin gallate and the study of polyphenol-protein association using multi-spectroscopic and computational methods. Physical Chemistry Chemical Physics: PCCP, 22(4), 2212–2228. https://doi.org/https://doi.org/10.1039/c9cp05301h
   PubMed Web of Science ®Google Scholar
• Dzeng, R. K., Jha, H. C., Lu, J., Saha, A., Banerjee, S., & Robertson, E. S. (2015). Small molecule growth inhibitors of human oncogenic gammaherpesvirus infected B-cells. Molecular Oncology, 9(2), 365–376. https://doi.org/https://doi.org/10.1016/j.molonc.2014.09.006
   PubMed Web of Science ®Google Scholar
• Grinde, B. (2013). Herpesviruses: Latency and reactivation – Viral strategies and host response. Journal of Oral Microbiology, 5(1), 22766. https://doi.org/https://doi.org/10.3402/jom.v5i0.22766
   PubMed Web of Science ®Google Scholar
• Hazarika, Z., & Jha, A. N. (2020). Computational analysis of the silver nanoparticle–human serum albumin complex. ACS Omega, 5(1), 170–178. https://doi.org/https://doi.org/10.1021/acsomega.9b02340
   PubMed Web of Science ®Google Scholar
• Hess, B., Bekker, H., Berendsen, H. J. C., & Fraaije, J. G. E. M. (1997). LINCS: A linear constraint solver for molecular simulations. Journal of Computational Chemistry, 18(12), 1463–1472. https://doi.org/https://doi.org/10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H
   Web of Science ®Google Scholar
• Hutchinson, L., Browne, H., Wargent, V., Davis-Poynter, N., Primorac, S., Goldsmith, K., Minson, A. C., & Johnson, D. C. (1992). A novel herpes simplex virus glycoprotein, gL, forms a complex with glycoprotein H (gH) and affects normal folding and surface expression of gH. Journal of Virology, 66(4), 2240–2250. https://doi.org/https://doi.org/10.1128/JVI.66.4.2240-2250.1992
   PubMed Web of Science ®Google Scholar
• Hutt-Fletcher, L. M. (2015). EBV glycoproteins: Where are we now? Future Virology, 10(10), 1155–1162. https://doi.org/https://doi.org/10.2217/fvl.15.80
   PubMed Web of Science ®Google Scholar
• Isaacs, C. E., Wen, G. Y., Xu, W., Jia, J. H., Rohan, L., Corbo, C., Di Maggio, V., Jenkins, E. C., Jr., & Hillier, S. (2008). Epigallocatechin gallate inactivates clinical isolates of herpes simplex virus. Antimicrobial Agents and Chemotherapy, 52(3), 962–970. https://doi.org/https://doi.org/10.1128/AAC.00825-07
   PubMed Web of Science ®Google Scholar
• Jassim, S. A. A., & Naji, M. A. (2003). Novel antiviral agents: A medicinal plant perspective. Journal of Applied Microbiology, 95(3), 412–427. https://doi.org/https://doi.org/10.1046/j.1365-2672.2003.02026.x
   PubMed Web of Science ®Google Scholar
• Jha, H. C., Banerjee, S., & Robertson, E. S. (2016). The role of gammaherpesviruses in cancer pathogenesis. Pathogens, 5(1), 18. https://doi.org/https://doi.org/10.3390/pathogens5010018
   Web of Science ®Google Scholar
• Jha, H. C., Mehta, D., Lu, J., El-Naccache, D., Shukla, S. K., Kovacsics, C., Kolson, D., & Robertson, E. S. (2015). Gammaherpesvirus infection of human neuronal cells. mBio, 6(6), e01844–e01815. https://doi.org/https://doi.org/10.1128/mBio.01844-15
   PubMed Web of Science ®Google Scholar
• Kapoor, R., Sharma, B., & Singh Kanwar, S. (2017). Antiviral phytochemicals: An overview. Biochemie und Physiologie der Pflanzen: BPP, 06(02), 220. https://doi.org/https://doi.org/10.4172/2168-9652.1000220
   Google Scholar
• Kirschner, A. N., Lowrey, A. S., Longnecker, R., & Jardetzky, T. S. (2007). Binding-site interactions between Epstein–Barr virus fusion proteins gp42 and gH/gL reveal a peptide that inhibits both epithelial and B-cell membrane fusion . Journal of Virology, 81(17), 9216–9229. https://doi.org/https://doi.org/10.1128/JVI.00575-07
   PubMed Web of Science ®Google Scholar
• Kozakov, D., Grove, L. E., Hall, D. R., Bohnuud, T., Mottarella, S. E., Luo, L., Xia, B., Beglov, D., & Vajda, S. (2015). The FTMap family of web servers for determining and characterizing ligand-binding hot spots of proteins. Nature Protocols, 10(5), 733–755. https://doi.org/https://doi.org/10.1038/nprot.2015.043
   PubMed Web of Science ®Google Scholar
• Kumari, R., Kumar, R., & Lynn, A. (2014). g_mmpbsa – A GROMACS tool for high-throughput MM-PBSA calculations. Journal of Chemical Information and Modeling, 54(7), 1951–1962. https://doi.org/https://doi.org/10.1021/ci500020m
   PubMed Web of Science ®Google Scholar
• Li, Q., Turk, S. M., & Hutt-Fletcher, L. M. (1995). The Epstein–Barr virus (EBV) BZLF2 gene product associates with the gH and gL homologs of EBV and carries an epitope critical to infection of B cells but not of epithelial cells. Journal of Virology, 69(7), 3987–3994. https://doi.org/https://doi.org/10.1128/JVI.69.7.3987-3994.1995
   PubMed Web of Science ®Google Scholar
• Liu, S., Li, H., Chen, L., Yang, L., Li, L., Tao, Y., Li, W., Li, Z., Liu, H., Tang, M., Bode, A. M., Dong, Z., & Cao, Y. (2013). (−)-Epigallocatechin-3-gallate inhibition of Epstein–Barr virus spontaneous lytic infection involves ERK1/2 and PI3-K/Akt signaling in EBV-positive cells. Carcinogenesis, 34(3), 627–637. https://doi.org/https://doi.org/10.1093/carcin/bgs364
   PubMed Web of Science ®Google Scholar
• Li, Y., Zhang, Y., Fu, M., Yao, Q., Zhuo, H., Lu, Q., Niu, X., Zhang, P., Pei, Y., & Zhang, K. (2012). Parthenolide induces apoptosis and lytic cytotoxicity in Epstein–Barr virus-positive Burkitt lymphoma. Molecular Medicine Reports, 6(3), 477–482. https://doi.org/https://doi.org/10.3892/mmr.2012.959
   PubMed Web of Science ®Google Scholar
• Machón, C., Fàbrega-Ferrer, M., Zhou, D., Cuervo, A., Carrascosa, J. L., Stuart, D. I., & Coll, M. (2019). Atomic structure of the Epstein–Barr virus portal. Nature Communications, 10(1), 3891. https://doi.org/https://doi.org/10.1038/s41467-019-11706-8
   PubMedGoogle Scholar
• Más, V., & Melero, J. A. (2013). Entry of enveloped viruses into host cells: Membrane fusion. Sub-Cellular Biochemistry, 68, 467–487. https://doi.org/https://doi.org/10.1007/978-94-007-6552-8_16
   PubMedGoogle Scholar
• Matsuura, H., Kirschner, A. N., Longnecker, R., & Jardetzky, T. S. (2010). Crystal structure of the Epstein–Barr virus (EBV) glycoprotein H/glycoprotein L (gH/gL) complex. Proceedings of the National Academy of Sciences of the United States of America, 107(52), 22641–22646. https://doi.org/https://doi.org/10.1073/pnas.1011806108
   PubMed Web of Science ®Google Scholar
• Matsuura, H., Kirschner, A. N., & Jardetzky, T. S. (2011). Crystal structure of the Epstein–Barr virus gH and gL complex. https://doi.org/https://doi.org/10.2210/pdb3phf/pdb
   Google Scholar
• Meng, X.-Y., Zhang, H.-X., Mezei, M., & Cui, M. (2011). Molecular docking: A powerful approach for structure-based drug discovery. Current Computer-Aided Drug Design, 7(2), 146–157. https://doi.org/https://doi.org/10.2174/157340911795677602
   PubMed Web of Science ®Google Scholar
• Möhl, B. S., Schröter, C., Klupp, B. G., Fuchs, W., Mettenleiter, T. C., Jardetzky, T. S., & Longnecker, R. (2015). Comparative mutagenesis of pseudorabies virus and Epstein–Barr virus gH identifies a structural determinant within domain III of gH required for surface expression and entry function. Journal of Virology, 90(5), 2285–2293. https://doi.org/https://doi.org/10.1128/JVI.03032-15
   PubMed Web of Science ®Google Scholar
• Molesworth, S. J., Lake, C. M., Borza, C. M., Turk, S. M., & Hutt-Fletcher, L. M. (2000). Epstein–Barr virus gH is essential for penetration of B cells but also plays a role in attachment of virus to epithelial cells. Journal of Virology, 74(14), 6324–6332. https://doi.org/https://doi.org/10.1128/jvi.74.14.6324-6332.2000
   PubMed Web of Science ®Google Scholar
• Mukhtar, M., Arshad, M., Ahmad, M., Pomerantz, R. J., Wigdahl, B., & Parveen, Z. (2008). Antiviral potentials of medicinal plants. Virus Research, 131(2), 111–120. https://doi.org/https://doi.org/10.1016/j.virusres.2007.09.008
   PubMed Web of Science ®Google Scholar
• Ng, P. C., & Henikoff, S. (2003). SIFT: Predicting amino acid changes that affect protein function. Nucleic Acids Research, 31(13), 3812–3814. https://doi.org/https://doi.org/10.1093/nar/gkg509
   PubMed Web of Science ®Google Scholar
• Pandey, S., Jha, H. C., Kumar Shukla, S., Shirley, M. K., & Robertson, E. S. (2018). Epigenetic regulation of tumor suppressors by enhances EBV-induced proliferation of gastric epithelial cells. mBio, 9(2), e00649-18. https://doi.org/https://doi.org/10.1128/mBio.00649-18
   PubMed Web of Science ®Google Scholar
• Parrinello, M., & Rahman, A. (1981). Polymorphic transitions in single crystals: A new molecular dynamics method. Journal of Applied Physics, 52(12), 7182–7190. https://doi.org/https://doi.org/10.1063/1.328693
   Web of Science ®Google Scholar
• Pei, Y., Hwang, N., Lang, F., Zhou, L., Hiu-Yuen Wong, J., Singh, R. K., Chandra Jha, H., El-Deiry, W. S., Du, Y., & Robertson, E. S. (2020). Quassinoid analogs with enhanced efficacy for treatment of hematologic malignancies target the PI3Kγ isoform. Communications Biology, 3(1), 267. https://doi.org/https://doi.org/10.1038/s42003-020-0996-z
   PubMed Web of Science ®Google Scholar
• Perez, E. M., Foley, J., Tison, T., Silva, R., & Ogembo, J. G. (2017). Novel Epstein–Barr virus-like particles incorporating gH/gL-EBNA1 or gB-LMP2 induce high neutralizing antibody titers and EBV-specific T-cell responses in immunized mice. Oncotarget, 8(12), 19255–19273. https://doi.org/https://doi.org/10.18632/oncotarget.13770
   PubMedGoogle Scholar
• Rajkhowa, S., Mayuri Borah, S., Nath Jha, A., & Deka, R. C. (2017). Design of plasmodium falciparum PI(4)KIIIβ inhibitor using molecular dynamics and molecular docking methods. ChemistrySelect, 2(5), 1783–1792. https://doi.org/https://doi.org/10.1002/slct.201601052
   Web of Science ®Google Scholar
• Rodrigues, C. H., Pires, D. E., & Ascher, D. B. (2018). DynaMut: Predicting the impact of mutations on protein conformation, flexibility and stability. Nucleic Acids Research, 46(W1), W350–W355. https://doi.org/https://doi.org/10.1093/nar/gky300
   PubMed Web of Science ®Google Scholar
• Rühl, J., Leung, C. S., & Münz, C. (2020). Vaccination against the Epstein–Barr virus. Cellular and Molecular Life Sciences: CMLS, 77(21), 4315–4324. https://doi.org/https://doi.org/10.1007/s00018-020-03538-3
   PubMed Web of Science ®Google Scholar
• Sathiyamoorthy, K., Xiong Hu, Y., Möhl, B. S., Chen, J., Longnecker, R., & Jardetzky, T. S. (2016). Structural basis for Epstein–Barr virus host cell tropism mediated by gp42 and gHgL entry glycoproteins. Nature Communications, 7, 13557. https://doi.org/https://doi.org/10.1038/ncomms13557
   PubMed Web of Science ®Google Scholar
• Sathiyamoorthy, K., Jiang, J., Hu, Y. X., Rowe, C. L., Möhl, B. S., Chen, J., Jiang, W., Mellins, E. D., Longnecker, R., Zhou, Z. H., & Jardetzky, T. S. (2014). Assembly and architecture of the EBV B cell entry triggering complex. PLoS Pathogens, 10(8), e1004309. https://doi.org/https://doi.org/10.1371/journal.ppat.1004309
   PubMed Web of Science ®Google Scholar
• Shibata, D., & Weiss, L. M. (1992). Epstein–Barr virus-associated gastric adenocarcinoma. The American Journal of Pathology, 140(4), 769–774. https://www.ncbi.nlm.nih.gov/pubmed/1314023
   PubMed Web of Science ®Google Scholar
• Singh, S., Homad, L. J., Akins, N. R., Stoffers, C. M., Lackhar, S., Malhi, H., Wan, Y.-H., Rawlings, D. J., & McGuire, A. T. (2020). Neutralizing antibodies protect against oral transmission of lymphocryptovirus. Cell Reports Medicine, 1(3), 100033. https://doi.org/https://doi.org/10.1016/j.xcrm.2020.100033
   PubMedGoogle Scholar
• Snijder, J., Ortego, M. S., Weidle, C., Stuart, A. B., Gray, M. D., Juliana McElrath, M., Pancera, M., Veesler, D., & McGuire, A. T. (2018). An antibody targeting the fusion machinery neutralizes dual-tropic infection and defines a site of vulnerability on Epstein–Barr virus. Immunity, 48(4), 799–811.e9. https://doi.org/https://doi.org/10.1016/j.immuni.2018.03.026
   PubMed Web of Science ®Google Scholar
• Stampfer, S. D., & Heldwein, E. E. (2013). Stuck in the middle: Structural insights into the role of the gH/gL heterodimer in herpesvirus entry. Current Opinion in Virology, 3(1), 13–19. https://doi.org/https://doi.org/10.1016/j.coviro.2012.10.005
   PubMed Web of Science ®Google Scholar
• Stroet, M., Caron, B., Visscher, K. M., Geerke, D. P., Malde, A. K., & Mark, A. E. (2018). Automated topology builder version 3.0: Prediction of solvation free enthalpies in water and hexane. Journal of Chemical Theory and Computation, 14(11), 5834–5845. https://doi.org/https://doi.org/10.1021/acs.jctc.8b00768
   PubMed Web of Science ®Google Scholar
• Tay, K.-C., Teng-Hern Tan, L., Kei Chan, C., Hong, S. L., Chan, K.-G., Hsum Yap, W., Pusparajah, P., Lee, L.-H., & Goh, B.-H. (2019). Formononetin: A review of its anticancer potentials and mechanisms. Frontiers in Pharmacology, 10, 820. https://doi.org/https://doi.org/10.3389/fphar.2019.00820
   PubMed Web of Science ®Google Scholar
• Thorley-Lawson, D. A., & Gross, A. (2004). Persistence of the Epstein–Barr virus and the origins of associated lymphomas. The New England Journal of Medicine, 350(13), 1328–1337. https://doi.org/https://doi.org/10.1056/NEJMra032015
   PubMed Web of Science ®Google Scholar
• Tian, W., Chen, C., Lei, X., Zhao, J., & Liang, J. (2018). CASTp 3.0: Computed atlas of surface topography of proteins. Nucleic Acids Research, 46(W1), W363–W367. https://doi.org/https://doi.org/10.1093/nar/gky473
   PubMed Web of Science ®Google Scholar
• Wang, X., Kenyon, W. J., Li, Q., Müllberg, J., & Hutt-Fletcher, L. M. (1998). Epstein–Barr virus uses different complexes of glycoproteins gH and gL to infect B lymphocytes and epithelial cells. Journal of Virology, 72(7), 5552–5558. https://doi.org/https://doi.org/10.1128/JVI.72.7.5552-5558.1998
   PubMed Web of Science ®Google Scholar
• Weber, C., Sliva, K., von Rhein, C., Kümmerer, B. M., & Schnierle, B. S. (2015). The green tea catechin, epigallocatechin gallate inhibits chikungunya virus infection. Antiviral Research, 113, 1–3. https://doi.org/https://doi.org/10.1016/j.antiviral.2014.11.001
   PubMed Web of Science ®Google Scholar
• Wu, L., Borza, C. M., & Hutt-Fletcher, L. M. (2005). Mutations of Epstein–Barr virus gH that are differentially able to support fusion with B cells or epithelial cells. Journal of Virology, 79(17), 10923–10930. https://doi.org/https://doi.org/10.1128/JVI.79.17.10923-10930.2005
   PubMed Web of Science ®Google Scholar
• Wu, L., & Hutt-Fletcher, L. M. (2007). Point mutations in EBV gH that abrogate or differentially affect B cell and epithelial cell fusion. Virology, 363(1), 148–155. https://doi.org/https://doi.org/10.1016/j.virol.2007.01.025
   PubMed Web of Science ®Google Scholar
• van Zyl, D. G., Mautner, J., & Delecluse, H.-J. (2019). Progress in EBV vaccines. Frontiers in Oncology, 9, 104. https://doi.org/https://doi.org/10.3389/fonc.2019.00104
   PubMed Web of Science ®Google Scholar